Publication of a transnational call for randomised interventional clinical trials by the ERA4Health partnership

Publication of the ERA4Health (Fostering a European Research Area for Health) partnership's transnational call for randomized interventional clinical trials: 'Investigator Initiated Clinical Trials in Cardiovascular, Autoimmune and Metabolic diseases (Trials4Health 2026)'

On 7 November 2025, the Ministry of Health (hereinafter referred to as the "MZD") publishes the following information in accordance with Act No. 130/2002 Coll., on the Support of Research, Experimental Development and Innovation from Public Funds and on Amendments to Certain Related Acts (Act on the Support of Research, Experimental Development and Innovation), as amended (hereinafter referred to as the "Act"),

the ERA4Health (Fostering a European Research Area for Health) partnership's transnational call for clinical trials: 'Investigator Initiated Clinical Trials in Cardiovascular, Autoimmune and Metabolic diseases (Trials4Health 2026)'

Call 2026

Deadline for announcement of results
October 2026

National budget allocation for the call
500 000 EUR

Maximum amount of support per project
250 000 EUR

Maximum aid intensity per project
Table: Maximum possible aid intensity by type of entity and type of research (according to the current version Methodology: European Partnerships in Health)

Applicants
research organisation, enterprise, patient organisations

Project duration
4years / 48 months

Deadlines for submission of project proposals:
Pre-proposals: 27 Jan 2026, 16:00 CET
Full proposals: 17 Jun 2026, 16:00 CEST

Interested parties can participate in the international information webinar on 13 November 2025. Registration is available from 7 November 2025 at this link: REGISTRATION

Documents

Conditions for the participation of the Czech applicant in ERA4Health IICS 2026

Methodology: European Partnerships for Health

Sub-programme 3: European Partnerships in Health - effective from 22.5.2024

Mandatory attachments of the Czech applicant for Phase 1 (pre-proposals)

  1. Affidavit on behalf of the tenderer or co-tenderer (PO)
  2. Affidavit on behalf of the tenderer or co-tenderer (FO)
  3. Affidavit for research organisations (if applicable)
  4. Affidavit of consortium composition (only if a Czech company is represented in the project)
  5. Budget tableAZV ČR Application Form)

Mandatory annexes of the Czech applicant for Phase 2 (full proposals)

  1. Affidavit of competence;
  2. Updated budget table AZV ČR Application Form)

Other documents

Commission Regulation

Frascati manual

Definition of types of results

The official call documents are available here

Information about the call

The ERA4Health Partnership's transnational call "Investigator Initiated Clinical Trials in Cardiovascular, Autoimmune and Metabolic diseases" (Trials4Health 2026) "aims to:

  • Support randomised interventional clinical trials initiated by investigators from multiple countries, designed as pragmatic studies comparing efficacy and/or studies focusing on new uses of medicines;
  • Promote and facilitate transnational collaboration between clinical and public health research teams (hospitals, public health facilities and other healthcare organisations) conducting international studies comparing the effectiveness of treatments or studies on new uses of medicines.

Projects should take into account the following aspects: 

  • The proposed study must be a pragmatic study comparing the efficacy of the treatment and/or a study aimed at a new use of the medicinal product, designed as a randomised phase III intervention study.
  • Comparative effectiveness studies compare the use of currently approved or existing health interventions used in clinical practice in Europe, either with each other or with the current standard of care.
  • In the case of comparative effectiveness studies , existing approved health interventions should be taken into account, which may include, but are not limited to, diagnostic, screening, preventive and therapeutic interventions. Interventions may be pharmacological or non-pharmacological, such as well-defined, reproducible and targeted nutrition and lifestyle interventions, surgical interventions, prognostic methods, use of medical devices, nano and advanced health technologies, eHealth, digital interventions and other health interventions.
  • In the case of studies on new uses of medicines , the aim is to explore new indications for approved medicines. As this call is publicly funded, clinical trials with a commercial purpose are excluded, therefore only studies on new uses of medicines whose patent protection has expired are allowed.
  • Proposed studies must address at least one of these specific diseases or conditions:
    • cardiovascular disease,
    • metabolic disorders,
    • autoimmune diseases (not only autoimmune diseases based on antibodies, but also other immune-mediated inflammatory diseases).

Project proposals must clearly demonstrate the potential health and/or economic impacts as well as the added value of transnational clinical collaboration, and must use validated tools and methods to determine the burden of disease and to evaluation the effects of interventions, where they exist. 

Clinical trials conducted for direct commercial purposes and/or in medical fields other than those mentioned above are not covered by this call.

Size of the project consortium

Each project consortium must include at least 3 partners from 3 different EU Member States or associated countries whose funding organisations are participating in the call. Each of these partners must be eligible and apply for funding from the relevant funding organisation. All 3 legal entities must be independent of each other. A maximum of 2 funding organisations from the same country are allowed per consortium . The project coordinator must be eligible for funding by its regional/national funding organisation participating in the call. The project coordinator may not be changed between the first and second phase. A maximum of 3 self-funding partners are allowed in a consortium . The maximum number of partners is 5, which can be increased to 6 or 7 if they include 1 or 2 countries respectively, namely the Czech Republic or Slovakia. Only transnational projects will be funded.

List of participating countries:

Belgium (KCE), Czech Republic (MZCR/AZVCR), France (FR MOH), Italy (IT MOH and FRRB), Lithuania (LMT), Latvia (LCS), Germany (BMFTR/DLR), Norway (RCN and HSØRHF), Poland (NCBR), Austria (FWF), Romania (UEFISCDI), Slovakia (CVTI SR), United Kingdom (DHSC-NIHR), Spain (CSCJA, ISCIII and DS-CAT), Sweden (SRC), Turkey (TÜSEB), global organisation Breakthrough T1D.

*The list of participating countries is current as of 6 November 2025.

Call rules:

The call is governed by transnational rules common to applicants from all participating countries. In addition to the transnational rules, Czech applicants must also comply with the national conditions set by the relevant national provider. Applicants participating in applied research projects will therefore have to comply with national conditions based on Sub-programme 3: European Partnerships in Health.

Contact persons:

Ing. Rachel Hengalová
Email: 
Tel: + 420 778 880 697

Mgr. Monika Kocmanová
Email: 
Tel: +420 778 973 186

You can also submit questions about the transnational call via email: .